Beijing Biostar Pharmaceuticals proposes 10-year share option scheme for employee incentives

• Beijing Biostar Pharmaceuticals adopted a proposed share option scheme on May 6, 2026, setting a 10-year term from adoption date, subject to shareholder approval at June 26, 2026 AGM.
• Scheme mandate limit set at 10% of issued H shares excluding treasury shares as of adoption date; service provider sublimit set at 2% of that cap.
• Individual annual grant cap set at 1% of issued share capital for employee participants; 0.2% for service providers.
• Options carry a minimum 12-month vesting period, typically vesting in three tranches over three years; exercise window runs from offer date to no later than 10 years from offer date.
• Subscription price set at no less than higher of grant-date close, five-day average close, or par value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260507-12152403), on May 07, 2026, and is solely responsible for the information contained therein.